指南与共识流行病学与生物统计临床试验与 GCP

竞争风险下复合终点使用标准——一项系统性文献调查及推荐

Criteria for use of composite end points for competing risks-a systematic survey of the literature with recommendations.
指南 / 共识 · J Clin Epidemiol · 2016-12-11

该系统综述检索MEDLINE、CINAHL、EMBASE、Cochrane图书馆及教科书至2015年4月,从63645条题录中纳入43篇文献,发现现有文献未提供竞争风险下使用复合终点的具体标准;作者推荐仅当竞争风险合理且发生频率足够高以影响对感兴趣终点干预效应解读时才使用复合终点,且这些标准很少被满足。

要点

  • 现有文献未提供竞争风险下使用复合终点的具体标准。
  • 作者推荐仅当竞争风险合理且发生频率足够高以影响解读时才使用复合终点。
  • 作者指出这些标准很少被满足。

核心结论

  • 现有文献未能就竞争风险下使用复合终点提供明确指导。
  • 作者推荐仅当竞争风险合理且发生频率足够高时才使用复合终点,且这些标准很少被满足。

研究设计与样本

  • 系统性文献调查,检索MEDLINE、CINAHL、EMBASE、Cochrane中央与系统评价数据库(含卫生技术评估数据库)及Cochrane方法学注册库,从建库至2015年4月,并检索候选教科书。
  • 从63645条题录和摘要中筛选出166篇可能相关文献,最终纳入43篇出版物。
  • 两名评价者独立筛选标题和摘要、独立审阅全文并提取作者提供的具体标准。

主要发现

  • 多数出版物将竞争风险作为使用复合终点的理由但未进一步阐述。
  • 没有任何文章或教科书章节提供竞争风险下使用复合终点的具体标准。
  • 一些文献主张使用复合终点以避免竞争风险所致偏倚,另一些则建议为此目的很少或从不使用复合终点。
  • 对《新英格兰医学杂志》发表的心力衰竭试验的回顾显示,许多试验使用死亡或住院的复合终点,但没有任何试验满足作者提出的标准。

关键数值与推荐

  • 作者推荐仅当竞争风险合理且发生频率足够高以影响对感兴趣终点干预效应解读时才使用复合终点。
  • 作者指出这些标准很少被满足。

临床怎么用

  • 作者建议仅当竞争风险合理且发生足够频繁时才使用复合终点,并指出这些标准很少被满足。

局限性

  • 现有文献未能就竞争风险下使用复合终点提供明确指导。
  • 没有任何文章或教科书章节提供竞争风险下使用复合终点的具体标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Composite end points are frequently used in reports of clinical trials. One rationale for the use of composite end points is to account for competing risks. In the presence of competing risks, the event rate of a specific event depends on the rates of other competing events. One proposed solution is to include all important competing events in one composite end point. Clinical trialists require guidance regarding when this approach is appropriate. OBJECTIVES: To identify publications describing criteria for use of composite end points for competing risk and to offer guidance regarding when a composite end point is appropriate on the basis of competing risks. METHODS, DATA SOURCES, STUDY SELECTION AND DATA EXTRACTION: We searched MEDLINE, CINAHL, EMBASE, The Cochrane's Central & Systematic Review databases including the Health Technology Assessment database, and the Cochrane's Methodology register from inception to April 2015, and candidate textbooks, to identify all articles providing guidance on this issue. Eligible publications explicitly addressed the issue of a composite outcome to address competing risks. Two reviewers independently screened the titles and abstracts for full-text review; independently reviewed full-text publications; and abstracted specific criteria authors offered for use of composite end points to address competing risks. RESULTS: Of 63,645 titles and abstracts, 166 proved potentially relevant of which 43 publications were included in the final review. Most publications note competing risks as a reason for using composite end points without further elaboration. None of the articles or textbook chapters provide specific criteria for use of composite end points for competing risk. Some advocate using composite end points to avoid bias due to competing risks and others suggest that composite end points seldom or never be used for this purpose. We recommend using composite end points for competing risks only if the competing risk is plausible and if it occurs with sufficiently high frequency to influence the interpretation of the effect of intervention on the end point of interest. These criteria will seldom be met. Review of heart failure trials published in the New England Journal of Medicine revealed that many of them use the composite end point of death or hospitalization; none of the trials, however, satisfied our criteria. CONCLUSION: The existing literature fails to provide clear guidance regarding use of composite end point for competing risks. We recommend using composite end points for competing risks only if the competing risk is plausible and if it occurs sufficiently often.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Manja V, AlBashir S, Guyatt G, et al. Criteria for use of composite end points for competing risks-a systematic survey of the literature with recommendations. J Clin Epidemiol. 2016. PMID: 27965044. doi:10.1016/j.jclinepi.2016.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。